强生首季多赚55% 胜市场预期
强生(Johnson & Johnson)首季盈利增长55%至58亿美元,经调整後每股盈利为2.3美元,优於市场预期的2.01美元。收入上升3.3%至206.9亿美元,市场预期为197.3亿美元。同时强生还将季度股息提高至每股1.01美元
强生首季医疗设备销售额下降8.2%至59.3亿美元,当中高利润率的骨科手术及视力矫正产品受到的打击尤其严重。受癌症药物Darzalex及Imbruvica需求的推动下,药品销售额增长8.7%至111.3亿美元。消费者保健销售增长9.2%至36.3亿美元,因在疫情下民众对止痛及退烧药Tylenol等产品的需求激增。
强生下调对今年的盈利预测至7.5至7.9美元,低於此前预计的8.95美元至9.1美元,因医疗器械业务受到打击,如髋关节及膝关节置换手术被延期。不过强生预期在疫情过後,医疗器械业务将在第四季度开始复苏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.